Hello, Guest!
  • Friday, November 15, 2024

Eli Lilly Receives $625M Army Contract Modification for COVID-19 Antibody Therapy

Eli Lilly and Co. (NYSE: LLY) has secured a $625 million contract modification to supply 500,000 more doses of the company’s COVID-19 monoclonal antibody drug to the U.S. Army.

Army Contracting Command obligated the full amount of the modification using fiscal 2021 Coronavirus Aid, Relief and Economic Security Act funds, the Department of Defense said Wednesday.

In November, the Food and Drug Administration granted emergency use authorization for Lilly’s LY-CoV555 antibody drug as a treatment for patients 12 years and older who have mild to moderate COVID-19 and at risk of developing severe coronavirus infection.

Bamlanivimab is intended to be administered via intravenous infusion, the company noted.

Video of the Day

Related Articles

Eli Lilly Books $2.7B in Army Contracts for Coronavirus Antibody Treatment Production Contract Awards

Eli Lilly Books $2.7B in Army Contracts for Coronavirus Antibody Treatment Production

Eli Lilly and Co. (NYSE: LLY) has received a pair of firm-fixed-price contracts worth $2.73 billion combined from the U.S. Army Contracting Command to produce monoclonal antibody drugs for COVID-19. The first contract, valued at $2.52 billion over nine months, covers the supply of coronavirus treatment that combines two neutralizing antibodies, LY-CoV555 and LY-CoV016 through

DoD, HHS Sign $375M Procurement Deal for Eli Lilly COVID-19 Drug Contract Awards

DoD, HHS Sign $375M Procurement Deal for Eli Lilly COVID-19 Drug

Eli Lilly and Co. (NYSE: LLY) has received a potential $375M contract from the departments of Defense and Health and Human Services to initially supply 300K doses of bamlanivimab, an investigational monoclonal antibody drug for COVID-19.

Health Agencies, Biopharmaceutical Firms Form Partnership to Accelerate COVID-19 Vaccine Development News

Health Agencies, Biopharmaceutical Firms Form Partnership to Accelerate COVID-19 Vaccine Development

The National Institutes of Health and three other U.S. health agencies have teamed up with the Foundation for the NIH, European Medicines Agency and 16 biopharmaceutical companies to speed up the development of vaccines and treatments for COVID-19. The Accelerating COVID-19 Therapeutic Interventions and Vaccines partnership will work to streamline clinical trials, coordinate regulatory processes and use assets to accelerate response to the coronavirus pandemic and other future health emergencies, NIH said Friday.